Abstract A controlled, randomised study was performed to evaluate the efficacy of treatment with heater probe in the prevention of rebleeding from peptic ulcer with a non-bleeding visible vessel. One hundred and one patients were randomised into two groups: patients to be treated by heater probe (n= 51) and controls without active treatment (n=50). In the heater probe group rebleeding occurred in five patients (10%) 
Bleeding from peptic ulcer persists or recurs early in 25% of cases,' which carries a high death rate related to the severity of bleeding or the need for surgical treatment. Endoscopic stigmata of recent haemorrhage allow the identification of lesions with a high risk of rebleeding. A nonbleeding visible vessel located in the crater of the ulcer has a 30-50% probability of recurrence.2" Therapeutic endoscopy with electrocoagulation, photocoagulation, or injection of sclerosant or vasoactive substances, has been effective in: (a) stopping active haemorrhage,'7-'l (b) diminishing the rebleeding rate,3467 '9 (c) reducing the need of surgery, "10 141617 and (d) decreasing the death rate. 8 1017 These results, however, are not uniform. [20] [21] [22] [23] Heater probe treatment of bleeding ulcer may be better than sclerosis with alcohol for stopping acute haemorrhage. 24 Heater probe may be less effective, however, than epinephrine injection in the initial control of active haemorrhage. 25 Heater probe is not superior to YAG laser or bipolar electrocoagulation in the immediate control of bleeding, decreasing the rebleeding rate, the need for surgery, or the death rate.626 Therefore, it remains to be proved whether the use of heater probe is better than no active treatment and a close observation of the patient. I 7 28 The aim of this study is to evaluate the efficacy of the heater probe in preventing recurrence of haemorrhage from peptic ulcer with a nonbleeding visible vessel. A control group without active treatment allowed us to compare the results.
Methods

PATIENTS
Between November 1988 and December 1991 all consecutive patients who were bleeding and admitted to the gastroenterology unit were considered for this study. Patients Limited haemorrhage -the presence of unchanged packed cell volume, haemodynamic stability, lack of haematemesis, no evidence of blood in the gastric aspirate, and normal stools or only traces of melaena.
Continued haemorrhage -(a) if the volume of intravenous fluids required to restore or maintain haemodynamic stability was greater than 1000 ml/hour or 3000 ml/12 hours, (b) fresh haematemesis and, (c) haematemesis or melaenas in association with a fall in packed cell volume greater than 5% in a 24 hour period, two days after admission.
Rebleeding -bloody gastric aspirate, haematemesis or melaenas while in the hospital, after initial control of bleeding, and the stools had become normal.
Haemodynamic stability -presence of all of the following, (a) systolic blood pressure greater than 100 mm Hg, (b) heart rate less than 100 beats/min, (c) urine output greater than 35 ml/hour and, (d) no signs or symptoms of impaired systemic perfusion.
ASSESSMENT
The efficacy of the heater probe was assessed with the results obtained at the first attempt. Data 
Results
One hundred and one patients were included in the study. Thirty five had bleeding gastric ulcer and sixty six a duodenal ulcer. After randomisation 51 patients were included in the heater probe group and 50 in the control group. Table I shows the clinical data on admission.
In the heater probe group, coagulation was achieved in 49 patients. The two patients in whom coagulation was not achieved had ulcers located in the inferior and posterior wall of the duodenal bulb, respectively. The approach to the visible vessel was difficult in 10 patients. The probe was applied from the front in 32 and laterally in 17 cases. A mean of8A4 pulses and 21 1 joules, were used in each patient, with the 2-3 mm probe in four cases and 3-2 mm probe in the remainder. Four patients bled during the procedure. In three of them, bleeding was finally controlled during the same session. The fourth patient required local epinephrine injection in addition to repeated heater probe pulses and was considered a failure in the final statistical analysis. In four additional patients bleeding recurred after heater probe treatment and in one of them, with high surgical risk, successful control of haemorrhage was obtained in a second thermocoagulation session. The remaining three patients required operations. In one of these three patients the bleeding started in another ulcer not seen during the first endoscopy and therefore not treated with heater probe. Thus, (Tables II and  III) . The incidence of rebleeding was lower in the heater probe treated patients than in the control group (Fisher's exact test p=003) with a comparative risk of 0 38 (95% CI 0 14 to 0 98). The difference in proportions of successful treatment in each group was 16-2% in favour of heater probe, with a 95% CI ranging from 2% to 31%. There were no significant differences between both groups in death, transfusion requirements, and days needed in hospital.
When the adherence to treatment is considered, the data analysis results are very similar to those seen in the intention to treat analysis (10- 90% of the patients. The two patients in whom the lesion was not reached had ulcers located in the inferior and posterior wall of duodenal bulb. The treatment was satisfactorily performed in all patients despite some difficulties in reaching the lesion in 20% of them. In the group of patients treated with the heater probe the incidence of rebleeding was about one third of that in the control group. There was no death in the endoscopy treated group. The only complication in this group was an uncontrolled haemorrhage induced by probe manipulation. The blood transfusion requirements were similar in both groups. Differences in days spent in hospital, however, amount of blood transfused, and operations required, are difficult to analyse because heater probe was an option for rescue treatment in the control group. Endoscopic treatment has been shown to be beneficial in bleeding patients.10'I Thus heater probe treatment was considered an option for rescue treatment in high risk patients. This decision was made based on ethical consideration despite the fact that the use of the heater probe as a rescue treatment would be a confounding variable in the assessment of the subsequent outcome (operation or death). Nevertheless, this strategy did not affect the results at the end point established in the methods (rebleeding).
It should be pointed out that in our control group, the incidence of rebleeding was 26%, which is less than the 30 to 50% seen by others. In these two studies the statistical power is lower than the conventional 80% required to reject a true effectiveness with statistical confidence. In addition, the results of two different studies have been published in abstract form,2839 one of these claiming a therapeutic benefit for heater probe. 28 This study, including estimation of sample size and the methods used, was aimed at avoiding problems with statistical evaluation of the results. The inaccessible lesions were included in the final analysis as the aim was to evaluate this procedure according to the intention to treat. Only the results from the first treatment with the heater probe were included in the statistical analysis although a definitive control of the bleeding was achieved sometimes after additional sessions. Finally, rebleeding from a previously missed and non-treated ulcer was considered a failure.
A meta analysis including our data and data obtained from previous publications2739 was performed to further evaluate the effectiveness of the heater probe, according to the DerSimonian-Laird method in rates differences estimation and the Mantel-Haenszel-Peto method by odds ratio. 40 The results of the meta analysis suggest that the heater probe is useful in the treatment of bleeding ulcers. The combined total number of patients included in the above mentioned studies is 428, 220 treated and 208 in the control group. The mean rate of recurrent or continued bleeding in control groups was 37%.
In the heater probe group the incidence of bleeding was lowered to 14% (pooled rate difference 95% CI= -0-23 (0-08)) and the typical odds ratio of uncontrolled haemorrhage was 0-29 (95% CI=0 19 to 0 45) favouring the heater probe. In ulcers with a non-bleeding visible vessel, the mean rate of rebleeding was 33% in control groups, the reduction as a result of treatment 19% (pooled rate difference 95% CI=0-19 (0-09)) and the odds ratio 0-37 (95% CI=0-21 to 0-65).
In summary, this study shows that compared with medical treatment the heater probe reduces the rebleeding rate in a non-bleeding visible vessel by 62%, there was no death, and complications were minimal. Our results suggest that heater probe is an effective and safe procedure in the prevention of recurrent haemorrhage in peptic ulcer with a non-bleeding visible vessel. 
